In vitro evidence revealed that clinically relevant interactions of DLM with drugs, particularly those whose disposition is dependent on ATP-binding cassette (ABC) and solute carrier transporters, breast cancer-resistant proteins (BCRP/ABCG2), organic anion-transporting polypeptides, or organic cation transporter 1, are impossible (Hu et al., 2016). Here, ABCG2 is linked to breast cancer.